Sep 26, 2025

Featuring an interview with Dr Kevin Kalinsky, including the following topics:

• Patient-Reported Outcomes from the TROPION-Breast01 Study (0:00)
  • Pernas S et al. Datopotamab deruxtecan (Dato-DXd) vs chemotherapy (CT) in previously treated inoperable or metastatic hormone receptor-positive, HER2-negative (HR+/HER2-)...

Sep 23, 2025

Featuring an interview with Prof Peter Schmid, including the following topics:

• Response to immunotherapy in breast cancer subtypes (0:00)
• Tolerability of TROP2 antibody-drug conjugates (ADCs) for metastatic breast cancer (mBC) (3:51)
• Approaches to therapy for patients with HR-negative HER2-low and HER2-ultralow mBC...

Sep 22, 2025

Featuring a slide presentation and related discussion from Prof Peter Schmid, including the following topics:

• Evolution of the therapeutic landscape for metastatic triple-negative breast cancer; age of immunotherapy (0:00)
• Case: A woman in her early 40s with no actionable mutations (7:29)
• Evolution of antibody-drug...

Sep 21, 2025

Featuring an interview with Dr Jonathan Strosberg, including the following topics:

• Overview of extrapulmonary neuroendocrine carcinoma (NEC) (0:00)
• Treatment strategies for extrapulmonary NEC (10:26)
• Targeting DLL3 in extrapulmonary NEC (18:49)
• Early clinical data with obrixtamig for extrapulmonary...

Sep 20, 2025

Featuring an interview with Dr Beth Faiman, including the following topics:

• Clinical practice background and historical view of treatment for multiple myeloma (MM) (0:00)
• Fundamental principles associated with chimeric antigen receptor (CAR) T-cell therapy (7:19)
• Sequencing of CAR T-cell therapy and bispecific...